| Literature DB >> 33270160 |
Diana Bonderman1, Gerhard Pölzl2, Klemens Ablasser3, Hermine Agis4, Stefan Aschauer5, Michaela Auer-Grumbach6, Christina Binder5, Jakob Dörler2, Franz Duca5, Christian Ebner7, Marcus Hacker8, Renate Kain9, Andreas Kammerlander5, Matthias Koschutnik5, Alexander Stephan Kroiss10, Agnes Mayr11, Christian Nitsche5, Peter P Rainer3, Susanne Reiter-Malmqvist12, Matthias Schneider5, Roland Schwarz13, Nicolas Verheyen3, Thomas Weber14, Marc Michael Zaruba2, Roza Badr Eslam5, Martin Hülsmann5, Julia Mascherbauer5.
Abstract
The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, the number of patients diagnosed with cardiac amyloidosis has increased significantly recently due to growing awareness of the disease, improved diagnostic capabilities and demographic trends. Specific therapies that improve patient prognosis have become available for certain types of cardiac amyloidosis. Thus, the earliest possible referral of patients with suspicion of cardiac amyloidosis to an experienced center is crucial to ensure rapid diagnosis, early initiation of treatment, and structured patient care. This requires intensive collaboration across several disciplines, and between resident physicians and specialized centers. The aim of this consensus statement is to provide guidance for the rapid and efficient diagnosis and treatment of light-chain amyloidosis and transthyretin amyloidosis, which are the most common forms of cardiac amyloidosis.Entities:
Keywords: 99mTc-DPD scan; Biopsy; Cardiac MRI; Cardiomyopathy; Heart failure
Year: 2020 PMID： 33270160 DOI： 10.1007/s00508-020-01781-z
Source DB: PubMed Journal: Wien Klin Wochenschr ISSN： 0043-5325 Impact factor: 1.704